TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Take a Stand ! - a Cluster Randomized Controlled Intervention Study at Four Office-based Workplaces Aiming to Reduce Occupational Sitting Time
Brief Summary: The purpose of the study is to test an intervention aiming to reduce sitting time during work hours among office workers.

Expectations according to outcome measures: Sitting time reduced by 1 hour pr. day (primary). Number of prolonged periods reduced by 1 pr. day (primary). Number of breaks increased by 3 pr. day (primary). 20 % of participants report a reduction of musculoskeletal pain (secondary). A reduction in waist circumference of 1 cm (secondary). A reduction of 0.5 % in bodyfat (secondary).


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ALIVE | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ALIVE; Assigned to Arm(s): Intervention
B: Arm Label: tailored group; Type: EXPERIMENTAL; Interventions: Behavioral: Start to stand | Arm Label: generic group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: generic advice | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Start to stand; Assigned to Arm(s): tailored group | Intervention Type: BEHAVIORAL; Name: generic advice; Assigned to Arm(s): generic group
C: Arm Label: Sitting time Change Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Sitting time Change Intervention | Arm Label: Active Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sitting time Change Intervention; Assigned to Arm(s): Sitting time Change Intervention
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention group | Arm Label: Intervention control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control group | Intervention Type: BEHAVIORAL; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Control group; Assigned to Arm(s): Intervention control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Take a Stand ! - a Cluster Randomized Controlled Intervention Study at Four Office-based Workplaces Aiming to Reduce Occupational Sitting Time
Brief Summary: The purpose of the study is to test an intervention aiming to reduce sitting time during work hours among office workers.

Expectations according to outcome measures: Sitting time reduced by 1 hour pr. day (primary). Number of prolonged periods reduced by 1 pr. day (primary). Number of breaks increased by 3 pr. day (primary). 20 % of participants report a reduction of musculoskeletal pain (secondary). A reduction in waist circumference of 1 cm (secondary). A reduction of 0.5 % in bodyfat (secondary).


Options:
A: Arm Label: Short breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short breaks | Arm Label: Long breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Long breaks | Intervention Type: BEHAVIORAL; Name: Short breaks; Assigned to Arm(s): Short breaks | Intervention Type: BEHAVIORAL; Name: Long breaks; Assigned to Arm(s): Long breaks
B: Arm Label: Reduction in sitting time; Type: EXPERIMENTAL; Interventions: Behavioral: Sedentary behavior | Arm Label: Increase in sit-to-stand transitions; Type: EXPERIMENTAL; Interventions: Behavioral: Sedentary behavior | Intervention Type: BEHAVIORAL; Name: Sedentary behavior; Assigned to Arm(s): Increase in sit-to-stand transitions, Reduction in sitting time
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention group | Arm Label: Intervention control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control group | Intervention Type: BEHAVIORAL; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Control group; Assigned to Arm(s): Intervention control
D: Arm Label: multi-component intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Sit-stand workstation only; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Usual practice (seated workstation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sit-stand workstation provision; Assigned to Arm(s): Sit-stand workstation only, multi-component intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Take a Stand ! - a Cluster Randomized Controlled Intervention Study at Four Office-based Workplaces Aiming to Reduce Occupational Sitting Time
Brief Summary: The purpose of the study is to test an intervention aiming to reduce sitting time during work hours among office workers.

Expectations according to outcome measures: Sitting time reduced by 1 hour pr. day (primary). Number of prolonged periods reduced by 1 pr. day (primary). Number of breaks increased by 3 pr. day (primary). 20 % of participants report a reduction of musculoskeletal pain (secondary). A reduction in waist circumference of 1 cm (secondary). A reduction of 0.5 % in bodyfat (secondary).


Options:
A: Arm Label: Biopsychosocial; Type: EXPERIMENTAL; Interventions: Behavioral: Biopsychosocial | Arm Label: Reference; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reference | Intervention Type: BEHAVIORAL; Name: Biopsychosocial; Assigned to Arm(s): Biopsychosocial | Intervention Type: BEHAVIORAL; Name: Reference; Assigned to Arm(s): Reference
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Sit-stand workstation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Sit-stand workstation; Assigned to Arm(s): Intervention
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention group | Arm Label: Intervention control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control group | Intervention Type: BEHAVIORAL; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Control group; Assigned to Arm(s): Intervention control
D: Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: Active Workstation Intervention, Behavioral: Ergonomic Intervention, Behavioral: Email Intervention, Device: Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application. | Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ergonomic Intervention, Behavioral: Email Intervention, Device: Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application. | Intervention Type: BEHAVIORAL; Name: Active Workstation Intervention; Assigned to Arm(s): Experimental Group | Intervention Type: BEHAVIORAL; Name: Ergonomic Intervention; Assigned to Arm(s): Active Control, Experimental Group | Intervention Type: BEHAVIORAL; Name: Email Intervention; Assigned to Arm(s): Active Control, Experimental Group | Intervention Type: DEVICE; Name: Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.; Assigned to Arm(s): Active Control, Experimental Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer
Brief Summary: The primary purpose of this study is to determine the non-inferiority of overall survival XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.


Options:
A: Arm Label: TAS-102; Type: EXPERIMENTAL; Interventions: Drug: TAS-102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TAS-102; Assigned to Arm(s): TAS-102 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Regorafenib (Stivarga, BAY73-4506)+BSC; Type: EXPERIMENTAL; Interventions: Drug: Regorafenib (Stivarga, BAY73-4506), Other: Best Supportive Care (BSC) | Arm Label: Placebo+BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Regorafenib (Stivarga, BAY73-4506); Assigned to Arm(s): Regorafenib (Stivarga, BAY73-4506)+BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+BSC | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo+BSC, Regorafenib (Stivarga, BAY73-4506)+BSC
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: FOLFIRI | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: FOLFIRI | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: FOLFIRI; Assigned to Arm(s): 1, 2
D: Arm Label: FOLFIRI +/- Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Drug: CPT-11 (Irinotecan), Drug: 5-FU Bolus, Drug: 5-FU Infusion, Drug: l-LV (dl-LV) | Arm Label: XELIRI +/- Bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: CPT-11 (Irinotecan), Drug: Capecitabine | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Bolus; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Infusion; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: l-LV (dl-LV); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): XELIRI +/- Bevacizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MOVE - A Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).


Options:
A: Arm Label: patients with COPD; Type: N/A; Interventions: N/A | Arm Label: smoking controls; Type: N/A; Interventions: N/A | Arm Label: non-smoking controls; Type: N/A; Interventions: N/A
B: Arm Label: Treatment sequence I; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVA149, Drug: Placebo | Arm Label: Treatment sequence II; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVA149, Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): Treatment sequence I, Treatment sequence II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment sequence I, Treatment sequence II
C: Arm Label: Aclidinium bromide; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised COPD Rehabilitation (control group) | Arm Label: Online COPD rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Online COPD rehabilitation (experimental) | Intervention Type: BEHAVIORAL; Name: Supervised COPD Rehabilitation (control group); Assigned to Arm(s): Control group | Intervention Type: BEHAVIORAL; Name: Online COPD rehabilitation (experimental); Assigned to Arm(s): Online COPD rehabilitation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MOVE - A Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).


Options:
A: Arm Label: Fluticasone Furoate / GW642444 (vilanterol); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg | Arm Label: Fluticasone Propionate / salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate 250mcg/ salmeterol 50mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg; Assigned to Arm(s): Fluticasone Furoate / GW642444 (vilanterol) | Intervention Type: DRUG; Name: Fluticasone Propionate 250mcg/ salmeterol 50mcg; Assigned to Arm(s): Fluticasone Propionate / salmeterol
B: Arm Label: GSK573719/GW642444 125/25; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 125/25 | Arm Label: GSK573719/GW642444 62.5/25; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 62.5/25 | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Arm Label: tiotropium bromide; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium bromide | Intervention Type: DRUG; Name: GSK573719/GW642444 125/25; Assigned to Arm(s): GSK573719/GW642444 125/25 | Intervention Type: DRUG; Name: GSK573719/GW642444 62.5/25; Assigned to Arm(s): GSK573719/GW642444 62.5/25 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: tiotropium bromide; Assigned to Arm(s): tiotropium bromide
C: Arm Label: Glycopyrronium bromide 50 μg; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium bromide | Arm Label: Placebo to glycopyrronium bromide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to glycopyrronium bromide | Arm Label: Tiotropium 18 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Intervention Type: DRUG; Name: Glycopyrronium bromide; Assigned to Arm(s): Glycopyrronium bromide 50 μg | Intervention Type: DRUG; Name: Placebo to glycopyrronium bromide; Assigned to Arm(s): Placebo to glycopyrronium bromide | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium 18 μg
D: Arm Label: Treatment sequence I; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVA149, Drug: Placebo | Arm Label: Treatment sequence II; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVA149, Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): Treatment sequence I, Treatment sequence II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment sequence I, Treatment sequence II

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke
Brief Summary: This study, E-COMPASS is a phase IV clinical trial designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. This study will enroll 75 subacute stroke patients with unilateral motor dysfunction. Primary objective is to demonstrate the efficacy of porcine brain peptide to improve motor recovery measured by the improvement ratio of Fugl-Meyer assessment ((score of FMA after 3 weeks - score of FMA at baseline) / score of FMA at baseline) in patients with subacute stroke.


Options:
A: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
B: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
C: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
D: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke
Brief Summary: This study, E-COMPASS is a phase IV clinical trial designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. This study will enroll 75 subacute stroke patients with unilateral motor dysfunction. Primary objective is to demonstrate the efficacy of porcine brain peptide to improve motor recovery measured by the improvement ratio of Fugl-Meyer assessment ((score of FMA after 3 weeks - score of FMA at baseline) / score of FMA at baseline) in patients with subacute stroke.


Options:
A: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
B: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
C: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
D: Arm Label: Cerebrolysin + donepezil; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin + donepezil | Arm Label: Cerebrolysin + placebo; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin + placebo | Arm Label: Donepezil + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil + placebo | Intervention Type: DRUG; Name: Cerebrolysin + donepezil; Assigned to Arm(s): Cerebrolysin + donepezil | Intervention Type: DRUG; Name: Cerebrolysin + placebo; Assigned to Arm(s): Cerebrolysin + placebo | Intervention Type: DRUG; Name: Donepezil + placebo; Assigned to Arm(s): Donepezil + placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke
Brief Summary: This study, E-COMPASS is a phase IV clinical trial designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. This study will enroll 75 subacute stroke patients with unilateral motor dysfunction. Primary objective is to demonstrate the efficacy of porcine brain peptide to improve motor recovery measured by the improvement ratio of Fugl-Meyer assessment ((score of FMA after 3 weeks - score of FMA at baseline) / score of FMA at baseline) in patients with subacute stroke.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
C: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke
Brief Summary: This study, E-COMPASS is a phase IV clinical trial designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. This study will enroll 75 subacute stroke patients with unilateral motor dysfunction. Primary objective is to demonstrate the efficacy of porcine brain peptide to improve motor recovery measured by the improvement ratio of Fugl-Meyer assessment ((score of FMA after 3 weeks - score of FMA at baseline) / score of FMA at baseline) in patients with subacute stroke.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
C: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
D: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A

Answer: C